{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:27Z","timestamp":1792410987270,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102254","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:32:21Z","timestamp":1708518741000},"page":"102254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6327-0176","authenticated-orcid":false,"given":"N.","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-0747","authenticated-orcid":false,"given":"R.","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"U.","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8501-5479","authenticated-orcid":false,"given":"M.","family":"Tomaszewska-Kiecana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-2069","authenticated-orcid":false,"given":"D.","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bourayou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-0380","authenticated-orcid":false,"given":"J.","family":"Powderly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.102254_bib1","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","article-title":"Immune checkpoints as therapeutic targets in autoimmunity","volume":"9","author":"Paluch","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102254_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-020-00862-w","article-title":"Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy","volume":"13","author":"Pan","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.102254_bib3","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102254_bib4","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2024.102254_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102254_bib6","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A\u00a0decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.102254_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102254_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib9020017","article-title":"Combined anti-cancer strategies based on anti-checkpoint inhibitor antibodies","volume":"9","author":"Golay","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.esmoop.2024.102254_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2024.102254_bib10","first-page":"87","article-title":"Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody [abstract P336]","volume":"5","author":"La Motte-Mohs","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2024.102254_bib11","first-page":"87","article-title":"A\u00a0phase 1 study of the safety, tolerability, and pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors [abstract P249]","volume":"5","author":"Lakhani","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2024.102254_bib12","first-page":"115","article-title":"First-in-human phase 1 study of INCMGA00012 in patients with advanced solid tumors: interim results of the cohort expansion phase [abstract P669]","volume":"6","author":"Mehnert","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2024.102254_bib13","first-page":"282","article-title":"A\u00a0phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results for patients with advanced cervical cancer (POD1UM-101) [abstract P394]","volume":"7","author":"Mehnert","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.102254_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102254_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size\u2013based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2024.102254_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2024.102254_bib17","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2024.102254_bib18","article-title":"Association of survival and immune-related adverse events with anti-PD-1\/PD-L1 and anti-CTLA-4 inhibitors, alone or their combination for the treatment of cancer: a systematic review and meta-analysis of 13 clinical trials","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102254_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.esmoop.2024.102254_bib20","author":"National Comprehensive Cancer Network"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102254_bib21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.102254_bib22","first-page":"A294","article-title":"A\u00a0phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101) [abstract 268]","volume":"8","author":"Berton-Rigaud","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2024.102254_bib23","first-page":"A1006","article-title":"Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: results from the POD1UM-101 study [abstract 956]","volume":"9","author":"Berton","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102254_bib24","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"6411","key":"10.1016\/j.esmoop.2024.102254_bib25","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for\u00a0PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.102254_bib26","doi-asserted-by":"crossref","first-page":"CT085","DOI":"10.1158\/1538-7445.AM2019-CT085","article-title":"Pharmacodynamic correlates in a phase I study of INCMGA00012, a PD-1 antagonistic monoclonal antibody [abstract]","volume":"79","author":"Condamine","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102254_bib27","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3802\/jgo.2019.30.e46","article-title":"Immunotherapy in endometrial cancer: new scenarios on the horizon","volume":"30","author":"Di Tucci","year":"2019","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102254_bib28","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3390\/ijms21072335","article-title":"Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions","volume":"21","author":"Kagabu","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102254_bib29","doi-asserted-by":"crossref","first-page":"Lmt36","DOI":"10.2217\/lmt-2020-0003","article-title":"Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver","volume":"9","author":"Kim","year":"2020","journal-title":"Lung Cancer Manag"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102254_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ph13110373","article-title":"First line immunotherapy for non-small cell lung cancer","volume":"13","author":"Nasser","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.esmoop.2024.102254_bib31","author":"US"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292400022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292400022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:40Z","timestamp":1761856300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292400022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S205970292400022X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102254","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102254"}}